JP7807815B2 - ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物 - Google Patents

ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物

Info

Publication number
JP7807815B2
JP7807815B2 JP2022550720A JP2022550720A JP7807815B2 JP 7807815 B2 JP7807815 B2 JP 7807815B2 JP 2022550720 A JP2022550720 A JP 2022550720A JP 2022550720 A JP2022550720 A JP 2022550720A JP 7807815 B2 JP7807815 B2 JP 7807815B2
Authority
JP
Japan
Prior art keywords
neuregulin
treatment
probnp
patient
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022550720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514738A (ja
JP2023514738A5 (https=
JPWO2021169845A5 (https=
Inventor
ズホウ ミングドング
Original Assignee
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． filed Critical ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Publication of JP2023514738A publication Critical patent/JP2023514738A/ja
Publication of JP2023514738A5 publication Critical patent/JP2023514738A5/ja
Publication of JPWO2021169845A5 publication Critical patent/JPWO2021169845A5/ja
Priority to JP2025205790A priority Critical patent/JP2026062640A/ja
Application granted granted Critical
Publication of JP7807815B2 publication Critical patent/JP7807815B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
JP2022550720A 2020-02-24 2021-02-19 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物 Active JP7807815B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025205790A JP2026062640A (ja) 2020-02-24 2025-11-27 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010113391.3 2020-02-24
CN202010113391 2020-02-24
CN202010174086.5 2020-03-13
CN202010174086.5A CN113289002A (zh) 2020-02-24 2020-03-13 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
PCT/CN2021/076772 WO2021169845A1 (zh) 2020-02-24 2021-02-19 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025205790A Division JP2026062640A (ja) 2020-02-24 2025-11-27 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物

Publications (4)

Publication Number Publication Date
JP2023514738A JP2023514738A (ja) 2023-04-07
JP2023514738A5 JP2023514738A5 (https=) 2024-02-29
JPWO2021169845A5 JPWO2021169845A5 (https=) 2024-02-29
JP7807815B2 true JP7807815B2 (ja) 2026-01-28

Family

ID=77317937

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022550720A Active JP7807815B2 (ja) 2020-02-24 2021-02-19 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物
JP2025205790A Pending JP2026062640A (ja) 2020-02-24 2025-11-27 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025205790A Pending JP2026062640A (ja) 2020-02-24 2025-11-27 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物

Country Status (8)

Country Link
US (1) US20230083149A1 (https=)
EP (1) EP4115899A4 (https=)
JP (2) JP7807815B2 (https=)
KR (1) KR20220145870A (https=)
CN (2) CN113289002A (https=)
AU (1) AU2021225283A1 (https=)
CA (1) CA3172439A1 (https=)
WO (1) WO2021169845A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117797243A (zh) * 2022-09-30 2024-04-02 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015501297A (ja) 2011-10-10 2015-01-15 ゼンスン（シャンハイ）サイエンスアンド テクノロジー リミテッドＺｅｎｓｕｎ（Ｓｈａｎｇｈａｉ）Ｓｃｉｅｎｃｅ ＆ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 心不全の治療用組成物および治療法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
JP2000502682A (ja) 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
JP2001519400A (ja) 1997-10-14 2001-10-23 ケンブリッジ ニューロサイエンス インク． ニューレグリン使用を含む治療法
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN104436167A (zh) * 2010-06-12 2015-03-25 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
EP2964249A1 (en) * 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015501297A (ja) 2011-10-10 2015-01-15 ゼンスン（シャンハイ）サイエンスアンド テクノロジー リミテッドＺｅｎｓｕｎ（Ｓｈａｎｇｈａｉ）Ｓｃｉｅｎｃｅ ＆ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 心不全の治療用組成物および治療法

Also Published As

Publication number Publication date
JP2023514738A (ja) 2023-04-07
CA3172439A1 (en) 2021-09-02
KR20220145870A (ko) 2022-10-31
WO2021169845A1 (zh) 2021-09-02
AU2021225283A1 (en) 2022-09-15
CN115515620A (zh) 2022-12-23
US20230083149A1 (en) 2023-03-16
EP4115899A4 (en) 2024-03-06
CN113289002A (zh) 2021-08-24
EP4115899A1 (en) 2023-01-11
JP2026062640A (ja) 2026-04-10

Similar Documents

Publication Publication Date Title
JP7761964B2 (ja) 心不全の治療用組成物
EP3199174B1 (en) Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia
JP2026062640A (ja) ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物
HK40086556A (en) Method for preventing, treating or delaying heart failure by using neuregulin, and composition
HK1231890B (en) Neuregulin for treating heart failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250729

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20251006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260108

R150 Certificate of patent or registration of utility model

Ref document number: 7807815

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150